Approved for: NSCLC
Osimertinib (Tagrisso) is a FDA-approved targeted therapy for non-small cell lung cancer (NSCLC) in adults whose tumors have certain EGFR gene mutations.
It is used:
- As adjuvant therapy after surgery to remove the tumor,
- As first-line therapy for metastatic disease, or For metastatic disease that got worse during or after treatment with another EGFR tyrosine kinase inhibitor.